Meta-Analysis and Systematic Review

Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis

Chan Meng

Abstract

Objective: The pathogenesis of polycystic ovarian syndrome (PCOS) remains unclear, but is known to be related to increased insulin resistance, diabetes, obesity, oxidative stress, inflammation, and cardiovascular disease. No meta-analyses have examined whether PCOS is associated with nitric oxide (NO). Therefore, we aimed to evaluate the association between serum/plasma nitrite levels and PCOS.

Methods: We performed a meta-analysis. To identify eligible original articles, we searched online computerized databases, including EMBASE, Medline, and Web of Science. The characteristics of each single study, as well as the standard mean difference (SMD) with corresponding confidence intervals (CIs), were calculated and subgroup analysis was performed to examine heterogeneity.

Results: We included 12 articles with 16 studies and a total of 895 patients were included in the meta-analysis. We found a significant association between PCOS and serum or plasma nitrite levels, with a pooled SMD of $-0.61$ (95% CI: $-1.05$ to $-0.16$). The final pooled data were determined by the random effects model because significant high heterogeneity ($I^2 = 89\%$) was found.

Conclusions: Our meta-analysis shows that decreased serum or plasma nitrite levels are associated with PCOS. The pathogenesis of PCOS may be due to endothelial dysfunction; however, further research to confirm this possibility is required.

Keywords

Polycystic ovarian syndrome (PCOS), nitric oxide, nitrite, meta-analysis, endothelial dysfunction, oxidative stress

Date received: 11 April 2019; accepted: 27 June 2019

Corresponding author:
Chan Meng, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Email: monica_828@163.com
**Introduction**

Polycystic ovarian syndrome (PCOS) is a common reproductive endocrine and metabolic disorder that affects 6% to 10% of women. PCOS is characterized by ovulatory dysfunction, menstrual irregularities hyperandrogenism, and polycystic ovaries. The pathogenesis of PCOS remains unclear, but is known to be related to increased insulin resistance, diabetes, obesity, oxidative stress, inflammation, and cardiovascular diseases. PCOS remains a syndrome and no single diagnostic criterion is sufficient for clinical diagnosis.

Insulin resistance plays an important role in the pathogenesis of PCOS. Hyperinsulinemia may contribute to the development of endothelial dysfunction, hypertension, diabetes, and dyslipidemia, and leads to an increased risk for metabolic disorders. Recent studies showed that high levels of advanced glycation end products and androgen induced inflammation and oxidative stress. These studies also showed a strong association between endothelial dysfunction and oxidative stress in the pathogenesis of PCOS, and these are prognostic indicators of cardiovascular disease, as well as recurrent pregnancy loss. Nitric oxide (NO) is one of the most important regulators of vascular physiology, such as neuronal transmission. NO is a relatively stable gas free radical that diffuses through the cell membrane. Nitric oxide is synthesized by nitric oxide synthase (NOS) during conversion of L-arginine using oxygen and NADPH as the cofactors. NO can adversely affect carbohydrates, proteins and lipids and, together with other inflammatory mediators, results in cell damage. NO plays an inevitable role under physiological and pathological conditions involved in regulation of vascular tone, blood pressure, vascular remodeling, and inflammation. Because of the short half-life of NO in vivo, measurement of NO levels in human is extremely difficult. However, NO produces the stable NO products of nitrate and nitrite. Previous studies have shown a causal relationship between NO and nitrite.

A recent study concluded that there was endothelial dysfunction in women with PCOS, even if they were young and non-obese. Studies have indicated that patients with PCOS are under high oxidative stress. In the past decade, various studies have examined nitrite in patients with PCOS and have investigated the associations between them. There is contradictory evidence on the level of nitrite in PCOS. Some studies have reported decreased nitrite levels in patients with PCOS, while some studies have found the opposite result. However, no meta-analyses have examined whether PCOS is associated with NO. Therefore, we conducted a meta-analysis to further examine the association between serum/plasma nitrite levels and PCOS (Supporting information: PRISMA Checklist).

**Material and methods**

**Search strategy**

Studies on PCOS and serum or plasma nitrite levels were identified. To identify all of the relevant original articles, we comprehensively searched a series of online computerized databases, including EMBASE, Medline, and Web of Science, using the key words “nitric oxide”, “nitrate”, “nitrite”, “nitrosamine”, “polycystic ovary syndrome”, and “PCOS” using the operator OR or AND. Papers were searched up to December 2018 and without limits of language. Reference sections from the identified literature were also reviewed in case of missing extra qualified papers. We first screened the titles and abstracts of the searched studies, and then evaluated the full article in case it contained data
regarding PCOS and serum or plasma nitrite levels. Two authors (MC and XXY) reviewed all abstracts and screened the reference lists. Disagreements were resolved by consensus.

**Inclusion and exclusion criteria and data extraction**

Original examinations were cautiously checked and there were no country limitations in our study. The inclusion criteria were as follows: (1) all examination and control subjects were limited to adults with PCOS and analyzed reliably by either the consensus statement declared at Rotterdam\textsuperscript{15} or National Institute of Health (NIH)\textsuperscript{16} criteria; (2) there was no significant difference in terms of body mass index (BMI) and age in the study and control groups; (3) studies were restricted to humans, contained original information, and were present in either full-text or abstract form; (4) studies reported serum/plasma nitrite levels; and (5) studies in which all PCOS group subjects did not have any conceivable inclining factors (such as Cushing syndrome, thyroid dysfunction, ovarian tumors) that may be related to their PCOS or those who were taking drugs (e.g., oral contraceptives, other hormonal treatments) at the time of the study. The exclusion criteria were as follows: (1) duplicate publications, case reports, abstracts, non-English, review articles, and editorials; and (2) the data were not sufficient for investigation or extraction of information.

**Data extraction**

Data were gathered for each study concerning the name of the first author, publication year, study design, sample size, age, nitrite levels, and BMI (mean ± standard deviation) in patients with PCOS and in control subjects.

**Risk of bias and statistical analysis**

We evaluated the quality of each individual included study using the Newcastle–Ottawa Scale.\textsuperscript{17} Meta-analysis was performed using Cochrane statistical software Review Manager 5.3 (Copenhagen, Denmark). When $P$ was $<0.05$, the random effects model was applied according to the $P$ value of chi-squared statistics. Heterogeneity was assessed by calculating the $I^2$ metric. An $I^2$ value $>75\%$ was considered as high heterogeneity, an $I^2$ value between 50\% and 75\% as moderate heterogeneity, and an $I^2$ value between 25\% and 50\% as low heterogeneity. An $I^2$ value $<25\%$ was considered homogeneous. If the $I^2$ value was $>50\%$ the random effects model was used and if the $I^2$ value was $<50\%$ the fixed effects model was used to combine effect size. We also performed subgroup analysis and meta-regression to determine the sources of heterogeneity. Repeated sensitivity analysis was performed to estimate the effect of each individual study in the meta-analysis by removing different individual studies each time. Nitrite levels in each study were calculated using the standard mean difference (SMD) with the 95\% confidence interval (CI).

**Results**

**Study selection**

Using our search strategy, we identified 98 potentially relevant articles from online electronic databases and one study from reference records. Subsequent to excluding copies, 88 records remained. After reading the titles or abstracts of these 88 studies, we excluded 54 articles according to inclusion criteria. When we screened the full text of the remaining 33 articles, 19 were excluded because they did not report adequate data,
one was not in English, and one study was a duplicate. Eventually, 12 articles including 16 studies satisfied the eligibility criteria. The selection process is shown in Figure 1 and the information of each study is shown in Table 1.

The meta-analysis included a total sample size of 895 (465 cases and 430 controls) and all of them were case-control studies. Three studies reported results separately for patients with obesity and PCOS and non-obese patients with PCOS, and one study reported plasma nitrite and nitrate study groups. Nine studies investigated European populations and three studies analyzed Asian populations.

**Meta-analysis results**

A Forest plot of the relationship of PCOS with serum or plasma nitrite levels is shown in Figure 2. We found a significant association between PCOS and serum or plasma nitrite levels, with a pooled SMD of $-0.61$ ($95\% \text{ CI: } -1.05 \text{ to } -0.16; P < 0.01$). High significant heterogeneity ($I^2 = 89\%$) was found among the studies. Therefore, the pooled data were determined by the random effects model.

**Subgroup analysis**

The SMD ($-0.09$) for a BMI $\geq 25 \text{ kg/m}^2$ in studies with a mean BMI $\geq 25 \text{ kg/m}^2$ was not
Table 1. Description of included studies in the meta-analysis.

| Source                        | Year | Country | Sample size (PCOS/CG) | Study Design | Mean BMI (kg/m²) | Mean age, years |
|-------------------------------|------|---------|-----------------------|-------------|------------------|-----------------|
| Baskol et al.                 | 2011 | Turkey  | 30/20                 | Case-control| 26.1 ± 3.1       | 28.2 ± 4.5      |
| Bayram et al.                 | 2011 | Turkey  | 45/17                 | Case-control| 23.8 ± 4.2       | 24.0 ± 6.0      |
| Erdogan et al.                | 2008 | Turkey  | 85/115                | Case-control| 23.33 ± 4.11     | 24.02 ± 1.30    |
| Guan A et al.                 | 2008 | China   | 15/12                 | Case-control| NA               | NA              |
| Guan B et al.                 | 2008 | China   | 10/11                 | Case-control| NA               | NA              |
| Karadeniz et al.              | 2011 | Turkey  | 98/93                 | Case-control| 24.25 ± 7.68     | 25.63 ± 7.67    |
| Kocer et al.                  | 2014 | Turkey  | 15/17                 | Case-control| 23.76 ± 4.44     | 22.73 ± 5.93    |
| Krishna et al.                | 2017 | India   | 29/20                 | Case-control| 24.96 ± 3.22     | 28 ± 2.52       |
| Kuscu et al.                  | 2009 | Turkey  | 31/23                 | Case-control| 21.89 ± 2.35     | 23.8 ± 4.37     |
| Su A et al.                   | 2012 | China   | 13/12                 | Case-control| 27.80 ± 5.87     | 26.80 ± 4.05    |
| Su B et al.                   | 2012 | China   | 12/12                 | Case-control| 22.01 ± 3.21     | 20.60 ± 2.75    |
| Taslipinar et al.             | 2014 | Turkey  | 25/25                 | Case-control| 26.35 ± 7.05     | 24.64 ± 4.93    |
| Turkcuoglu A et al.           | 2010 | Turkey  | 18/11                 | Case-control| 28.3 ± 2.4       | 29.6 ± 6.2      |
| Turkcuoglu B et al.           | 2010 | Turkey  | 22/24                 | Case-control| 20.8 ± 2.1       | 23.5 ± 4.7      |
| Willis A et al.               | 2014 | UK      | 17/18                 | Case-control| 30 ± 6           | 31 ± 6          |
| Willis B et al.               | 2014 | UK      | 17/18                 | Case-control| 30 ± 6           | 31 ± 6          |

PCOS, polycystic ovary syndrome; CG, control group; NA, not available; BMI, body mass index.

aData included patients with obesity and PCOS (group A) and non-obese patients with PCOS (group B).

bData included patients with obesity and plasma nitrite measurements (group A) and those with nitrate measurements (group B).

Mean values are shown as standard deviation.
significant (95% CI: -0.49 to 0.30, P > 0.01) (Figure 3). The SMD (−1.01) for a BMI < 25 kg/m² in studies with a mean BMI < 25 kg/m² was not significant (95% CI: −1.78 to −0.24, P > 0.01) (Figure 4). The SMD (−0.32) for age ≥ 25 years in studies with a mean age ≥ 25 years was not significant (95% CI: −1.11 to 0.48, P > 0.01) (Figure 5). The SMD (−0.80) for an age < 25 years in studies with a mean age < 25 years was not significant (95% CI: −1.62 to 0.01, P > 0.01) (Figure 6). The SMD (−1.27) for Asian ethnicity in studies with an Asian population was not significant (95% CI: −2.24 to −1.30, P > 0.01) (Figure 7). The SMD (−0.32) of European ethnicity in studies with a European population was not significant (95% CI: −0.77 to 0.13, P > 0.01) (Figure 8).

### Sensitivity analysis

Forest plots showed that our results had high heterogeneity (I² = 89%). Sensitivity analysis results showed that the pooled value ranged from −0.43 (95% CI: −0.82 to −0.05) to −0.68 (95% CI: −1.14 to −0.22). Additionally, subgroup heterogeneity was also analyzed (I² = 53% for BMI ≥ 25 kg/m²; I² = 94% for BMI < 25 kg/m²; I² = 91% for age ≥ 25 years; I² = 93% for age < 25 years; I² = 85% for an Asian population; I² = 88% for a European population). However, sensitivity analysis results were different in the subgroups. In the BMI ≥ 25 kg/m² subgroup, the results dramatically changed when Taslipinar et al.’s study was removed (I² decreased from 53% to 0%).

---

**Figure 2.** Relationship between polycystic ovary syndrome with serum or plasma nitrite levels. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.

**Figure 3.** Forest plot of body mass index ≥ 25 kg/m² in subgroup analysis. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.
**Figure 4.** Forest plot of body mass index \(<25\,\text{kg/m}^2\) in subgroup analysis. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.

| Study or Subgroup | Experimental Mean | SD | Total Mean | SD | Total Weight | Control Mean | SD | Total Mean | SD | Total Weight | IV | Standard | CI | Standard | CI | Standard | CI |
|-------------------|------------------|----|------------|----|-------------|-------------|----|------------|----|-------------|----|-----------|----|-----------|----|-----------|----|-----------|----|
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |

**Total (95% CI):** 337 321 100.0% -1.81 [-1.78, -0.86]

Heterogeneity: Tau^2 = 1.11; Chi^2 = 125.26; df = 7 (P = 0.00001); I^2 = 94%

Test for overall effect: Z = 2.58 (P = 0.010)

**Figure 5.** Forest plot of age \(\geq 25\) years in subgroup analysis. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.

| Study or Subgroup | Experimental Mean | SD | Total Mean | SD | Total Weight | Control Mean | SD | Total Mean | SD | Total Weight | IV | Standard | CI | Standard | CI | Standard | CI |
|-------------------|------------------|----|------------|----|-------------|-------------|----|------------|----|-------------|----|-----------|----|-----------|----|-----------|----|
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |

**Total (95% CI):** 309 180 100.0% -0.32 [-1.11, 0.48]

Heterogeneity: Tau^2 = 0.88; Chi^2 = 56.71; df = 5 (P < 0.00001); I^2 = 91%

Test for overall effect: Z = 0.75 (P = 0.43)

**Figure 6.** Forest plot of age \(< 25\) years in subgroup analysis. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.

| Study or Subgroup | Experimental Mean | SD | Total Mean | SD | Total Weight | Control Mean | SD | Total Mean | SD | Total Weight | IV | Standard | CI | Standard | CI | Standard | CI |
|-------------------|------------------|----|------------|----|-------------|-------------|----|------------|----|-------------|----|-----------|----|-----------|----|-----------|----|
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |

**Total (95% CI):** 223 221 100.0% -0.89 [-1.62, 0.81]

Heterogeneity: Tau^2 = 0.94; Chi^2 = 67.97; df = 5 (P < 0.00001); I^2 = 93%

Test for overall effect: Z = 1.93 (P = 0.05)

**Figure 7.** Forest plot of the Asian population in subgroup analysis. SD, standard deviation; std, standard; IV, inverse variance; CI, confidence interval.

| Study or Subgroup | Experimental Mean | SD | Total Mean | SD | Total Weight | Control Mean | SD | Total Mean | SD | Total Weight | IV | Standard | CI | Standard | CI | Standard | CI |
|-------------------|------------------|----|------------|----|-------------|-------------|----|------------|----|-------------|----|-----------|----|-----------|----|-----------|----|
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |
|                   |                  |    |            |    |             |             |    |            |    |             |    |           |    |           |    |           |    |

**Total (95% CI):** 79 67 100.0% -1.27 [-2.24, -0.30]

Heterogeneity: Tau^2 = 1.95; Chi^2 = 26.47; df = 4 (P < 0.0001); I^2 = 85%

Test for overall effect: Z = 2.56 (P = 0.01)
age ≥ 25 years subgroup, when we removed Krishna et al.’s study,\textsuperscript{23} the $I^2$ decreased from 91% to 0%. In the Asian population subgroup, when we removed Krishna et al.’s study,\textsuperscript{23} the $I^2$ decreased from 85% to 0%. Meta-regression analysis showed that the publication date may have been the source of heterogeneity (publication date: ≤2010, $P = 0.03$; country: Europe, $P = 0.10$; sample size: PCOS ≤30, $P = 0.78$).

**Quality assessment**

The trim and fill technique showed that no investigation should have been statistically corrected. Table 2 summarizes the consequences of the quality evaluation. The methodological quality was evaluated as high in three studies, moderate in six studies, and low in three studies.

**Discussion**

This meta-analysis showed that PCOS was associated with serum or plasma nitrite levels. Furthermore, in patients with PCOS, serum or plasma nitrite levels were reduced compared with controls. The value of $I^2 = 89$ showed that there was high heterogeneity. We also performed subgroup analysis and meta-regression to determine the sources of heterogeneity. Additionally, sensitivity analysis showed that when any individual study was overlooked, the general outcomes remained the same. Therefore, our meta-analysis results appear to be reliable.

The mechanisms of PCOS are not completely understood, but recent studies suggest that insulin resistance plays an important role in the pathogenesis of PCOS.\textsuperscript{3} Endothelial dysfunction, increased oxidative stress, decreased antioxidant defense, excess androgen levels, and dyslipidemia have important effects on cardiovascular disease in patients with PCOS.\textsuperscript{28} Orio et al.\textsuperscript{29} assessed youthful patients with PCOS and no metabolic and cardiovascular disease and reported disturbance in endothelial functions in the early period of this disease. However, Mather et al.\textsuperscript{30} showed normal endothelial function in patients with PCOS and no metabolic and cardiovascular disease. Kandarakis et al.\textsuperscript{31} indicated that high serum androgen levels in women with PCOS may add to impairment of endothelial structure and increased risk of cardiovascular disease. Our meta-analysis results support the outcomes from most previous studies\textsuperscript{18} because serum or plasma nitrite levels were lower in patients with PCOS than in controls.

Sorensen et al.\textsuperscript{32} reported that endothelial dysfunction in patients with PCOS is independent from age and BMI. Obesity is an additional burden and a risk factor in PCOS, and is involved in the pathogenesis.
| Study                | Selection | Representativeness | Ascertainment | Outcome of interest | Comparability | Outcome | Adequacy of FU | Total scorea |
|----------------------|-----------|-------------------|---------------|---------------------|---------------|---------|----------------|---------------|
| Baskol et al.18      | **        | *                 | _             | *                   | **            | _       | *              | 6             |
| Bayram et al.19      | **        | *                 | *             | *                   | *             | *       | *              | 8             |
| Erdogan et al.20     | **        | *                 | *             | _                   | _             | _       | _              | 5             |
| Guan A et al.21      | *         | *                 | *             | **                  | _             | _       | _              | 5             |
| Guan B et al.21      | *         | *                 | *             | **                  | _             | _       | _              | 6             |
| Karadeniz et al.12   | *         | *                 | _             | *                   | _             | _       | *              | 5             |
| Kocer et al.22       | *         | *                 | *             | *                   | _             | _       | _              | 7             |
| Krishna et al.23     | *         | *                 | *             | **                  | *             | _       | _              | 8             |
| Kuscu et al.24       | *         | *                 | *             | *                   | _             | _       | _              | 6             |
| Su A et al.25        | *         | *                 | _             | *                   | _             | _       | _              | 5             |
| Su B et al.25        | *         | *                 | _             | _                   | _             | _       | _              | 5             |
| Taslipinar et al.26   | *         | *                 | _             | *                   | *             | _       | _              | 6             |
| Turkcuoglu A et al.13| *         | *                 | *             | **                  | _             | _       | *              | 7             |
| Turkcuoglu B et al.13| *         | *                 | *             | **                  | _             | _       | *              | 7             |
| Willis A et al.27    | *         | *                 | _             | *                   | _             | _       | _              | 5             |
| Willis B et al.27    | *         | *                 | _             | 8                   | _             | _       | _              | 5             |

FU, follow-up.
— indicates no stars (*).

*aWe considered a study to be of high quality when the total score was 8 or 9 stars, moderate quality when the total score was 6 or 7 stars, and low quality when the total score was 5 stars or fewer.
of hyperandrogenism and insulin resistance. Cupisti et al.\textsuperscript{33} found that a high BMI (\(\geq 25\, \text{kg/m}^2\)) was the main factor for endocrinological and metabolic disturbances in women with PCOS. Willis et al.\textsuperscript{27} found that plasma nitrite and nitrate levels were unaltered in women with PCOS compared with age- and BMI-matched controls. Consistent with previous studies,\textsuperscript{32} our BMI and age subgroup analysis results were not significant. However, further research is required to determine the relationship between serum or plasma nitrite levels and obesity or BMI. There have been no studies on racial differences in NO levels across different ethnicities in women with PCOS. In our meta-analysis, there was no obvious difference in nitrite levels between Asian and European populations, but more studies in other ethnicities are required to evaluate if serum or plasma nitrite levels are influenced by ethnicity.

The relationship of PCOS with serum or plasma nitrite levels is controversial. Our meta-analysis is the first to support a relation of PCOS with serum or plasma nitrite levels. However, there are some potential limitations of our meta-analysis that should be considered when interpreting the results. First, despite that we investigated the source of heterogeneity, we only examined heterogeneity from the publication date because there was inadequate information and a limited amount of studies. Second, the number of studies was generally insufficient and may have affected the precision of our outcomes. Further larger scale studies need to be performed to confirm our results. Third, the outcomes may have been one-sided by various estimation methods and instruments used to identify serum or plasma nitrite levels. Furthermore, plasma nitrite and nitrate levels reflect not only endogenous NO production, but also dietary nitrate ingestion. Magnesium and vitamin E can increase plasma NO levels.\textsuperscript{34} Therefore, dietary variables may have affected our findings. Additionally, plasma NO status may sometimes not reflect tissue NO status. Finally, we could only include studies in the English language because of difficulty in obtaining abstracts or full texts of articles published in other languages. Therefore, our results need confirmation by further research and should be interpreted with caution.

**Conclusions**

Our meta-analysis shows that serum or plasma nitrite levels are reduced in patients with PCOS. The pathogenesis of PCOS may be due to endothelial dysfunction, but further research on this issue is required in the future.

**Author contributions**

All authors contributed significantly to this work. M.C. designed and performed the research; M.C. and X.X.Y. wrote and revised the manuscript. All authors approved the final draft of the manuscript.

**Declaration of conflicting interest**

The author declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**References**

1. Ahles BL. Toward a new approach: primary and preventive care of the women with polycystic ovarian syndrome. *Prim Care Update Ob Gyns* 2000; 7: 275–278.
2. Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. *Am J Obstet Gynecol* 1998; 179: 89–93.
3. Buyalos RP, Geffner ME, Bersch N, et al. Insulin and insulin-like growth factor-1 responsiveness in polycystic ovarian syndrome. *Fertil Steril* 1992; 57: 796–803.

4. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004; 19: 41–47.

5. Kandaraki E, Chatzigeorgiou A, Piperi C, et al. Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. *Mol Med* 2012; 18: 1183.

6. Sabuncu T, Vural H, Harma M, et al. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. *Clin Biochem* 2001; 34: 407–413.

7. Hoover DB, Chang Y, Hancock JC, et al. Actions of tachykinins within the heart and their relevance to cardiovascular disease. *Jpn J Pharmacol* 2000; 84: 367–373.

8. Stichtenoth DO and Frölich JC. Nitric oxide and inflammatory joint disease. *Br J Rheumatol* 1998; 37: 246–257.

9. Breit DS and Snyder SH. Nitric oxide: a physiologic messenger molecule. *Ann Rev Biochem* 1994; 63: 175–195.

10. Ghasemi A, Zahedi Asl S, Mehrabi Y, et al. Serum nitric oxide metabolite levels in a general healthy population: relation to sex and age. *Life Sci* 2008; 83: 326–331.

11. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. *Clin Endocrinol* 2013; 78: 438–446.

12. Karadeniz M. Effect of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocysteine levels in Turkish patients with polycystic ovary syndrome. *Lipids Health Dis* 2011; 10: 193–193.

13. Türkçıoğlu I, Engin-Üstün Y, Turan F, et al. Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. *Gynecol Endocrinol* 2011; 17: 6.

14. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 2015; 313: 1657–1665.

15. Group ESPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Fertil Steril* 2004; 81: 19–25.

16. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. *Minerva Ginecol* 2004; 56: 1–6.

17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603–605.

18. Baskol G, Aygen E, Erdem F, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. *Acta Obstet Gynecol Scand* 2012; 91: 326–330.

19. Bayram F, Kocer D, Ozsan M, et al. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. *Gynecol Endocrinol* 2012; 28: 5.

20. Erdogan M, Karadeniz M, Berdeli A, et al. The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients. *J Endocrinol Invest* 2008; 31: 624–629.

21. Guan Y, Yang X, Ren F, et al. Clinical study of serum nitric oxide levels and related factors in patients with polycystic ovary syndrome. *Chinese Journal of Obstetrics and Gynecology* 2008; 9: 217–219.

22. Kocer D, Bayram F and Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. *Gynecol Endocrinol* 2014; 30: 367–371.
23. Krishna MB, Joseph A, Thomas PL, et al. Impaired arginine metabolism coupled to a defective redox conduit contributes to low plasma nitric oxide in polycystic ovary syndrome. *Cell Physiol Biochem* 2017; 43: 1880–1892.

24. Kuscu NK and Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. *Acta Obstet Gynecol Scand* 2009; 88: 612–617.

25. Su Y. Determination of serum NO, SOD and MDA in patients with polycystic ovary syndrome and clinical. Dali University, 2012.

26. Yavuz Taslipinar M, Kilic N, Bayraktar N, et al. Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. *Turk J Med Sci* 2014; 44: 787–791.

27. Willis G, Udiawar M, Evans W, et al. Detailed characterisation of circulatory nitric oxide and free radical indices—is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome? *BJOG* 2015; 121: 1596–1603.

28. Yilmaz M, Bukan N, Ayvaz G, et al. The effects of and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. *Hum Reprod* 2005; 20: 3333–3340.

29. Orio F, Palomba S, Spinelli L, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004; 89: 4588–4593.

30. Mather KJ, Verma S, Corenblum B, et al. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000; 85: 1851–1856.

31. Diamanti-Kandarakis E, Spina G, Kouli C, et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. *J Clin Endocrinol Metab* 2001; 86: 4666–4673.

32. Sorensen MB, Franks S, Robertson C, et al. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. *Clin Endocrinol* 2006; 65: 655–659.

33. Cupisti S, Kajaia N, Dittrich R, et al. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. *Eur J Endocrinol* 2008; 158: 711–719.

34. Shokrpour M and Asemi Z. The effects of magnesium and vitamin E co-supplementation on hormonal status and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. *Biol Trace Elem Res* 2018; 30: 1–7.